Please login to the form below

Not currently logged in
Email:
Password:

Servier

This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

consumer health joint venture last month, and Shire has sold its oncology business to Servier.

Latest news

More from news
Approximately 18 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.

  • Deal Watch March 2017 Deal Watch March 2017

    name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and

  • Deal Watch January 2017 Deal Watch January 2017

    What goes around, comes around The appetite for immuno-oncology (IO) has survived well into 2017 with Servier closing the biggest IO headline deal in January with Pieris for $1.7bn ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1

  • Searching for health Searching for health

    The 27 hectare site, with two production plants making pharmaceuticals and cosmetics, is a crucial springboard for new therapies and the industry-wide commitment to rebuild after Servier's appetite suppressant

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics